

# Holly L Geyer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4293308/holly-l-geyer-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28 papers	442 citations	7 h-index	21 g-index
34 ext. papers	591 ext. citations	4.1 avg, IF	3.01 L-index

#	Paper	IF	Citations
28	Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study.. <i>JMIR Formative Research</i> , <b>2022</b> , 6, e33581	2.5	0
27	Wellness of hospitalists and hospital medicine advanced practice providers during the COVID-19 pandemic, 2020-2021.. <i>Journal of Hospital Medicine</i> , <b>2022</b> , 17, 259-267	2.7	1
26	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e227038	10.4	1
25	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection.. <i>Med</i> , <b>2021</b> ,	31.7	2
24	Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera. <i>Blood</i> , <b>2021</b> , 138, 3644-3644	2.2	
23	Why we still prescribe so many opioids: A qualitative study on -barriers and facilitators to prescribing guideline implementation. <i>Journal of Opioid Management</i> , <b>2021</b> , 17, 115-124	0.8	0
22	Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine. <i>Hospital Practice (1995)</i> , <b>2021</b> , 49, 245-251	2.2	1
21	Psychological wellness of internal medicine hospitalists during the COVID-19 pandemic. <i>Hospital Practice (1995)</i> , <b>2021</b> , 49, 47-55	2.2	6
20	An Institutional Approach to Managing the Opioid Crisis. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 968-981	6.4	3
19	How I treat pain in hematologic malignancies safely with opioid therapy. <i>Blood</i> , <b>2020</b> , 135, 2354-2364	2.2	1
18	Perception of barriers to research among internal medicine physician hospitalists by career stage. <i>Hospital Practice (1995)</i> , <b>2020</b> , 48, 206-212	2.2	0
17	Perspectives on and barriers to research among advanced practice provider and physician hospitalists. <i>Nurse Practitioner</i> , <b>2020</b> , 45, 41-47	0.4	2
16	Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 402-408	1.9	5
15	Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 398-402	4.7	5
14	Utilization of Patient-Reported Outcomes in Myeloproliferative Neoplasm Clinical Trials Registered at Clinicaltrials.Gov. <i>Blood</i> , <b>2018</b> , 132, 5469-5469	2.2	
13	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , <b>2017</b> , 102, 85-93	6.6	29
12	Approach to MPN Symptom Assessment. <i>Current Hematologic Malignancy Reports</i> , <b>2017</b> , 12, 381-388	4.4	4

11	A case of hypercalcaemia in an immunocompetent patient with intracellulare. <i>JRSM Open</i> , <b>2017</b> , 8, 2054279417316614		
10	Relation of Telemetry Use and Mortality Risk, Hospital Length of Stay, and Readmission Rates in Patients With Respiratory Illness. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1416-1420	3	2
9	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , <b>2017</b> , 63, 34-40	2.7	12
8	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , <b>2016</b> , 122, 1888-96	6.4	11
7	Emerging drugs for the treatment of myelofibrosis. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 663-78	3.7	5
6	Management of symptoms in polycythemia vera and essential thrombocythemia patients. <i>Hematology American Society of Hematology Education Program</i> , <b>2015</b> , 2015, 340-8	3.1	10
5	Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 284706	4.3	70
4	Assessing disease burden in patients with classic MPNs. <i>Best Practice and Research in Clinical Haematology</i> , <b>2014</b> , 27, 107-19	4.2	6
3	Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4098-103	2.2	252
2	JAK2 inhibitors and their impact in myeloproliferative neoplasms. <i>Hematology</i> , <b>2012</b> , 17 Suppl 1, S129-32	2.2	7
1	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19		3